Tenecteplase thrombolysis — Competitive Intelligence Brief

Tenecteplase thrombolysis (Tenecteplase thrombolysis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent / Thrombolytic. Area: Cardiovascular.

marketed Fibrinolytic agent / Thrombolytic Fibrin; Plasminogen Cardiovascular Small molecule

Target snapshot

Tenecteplase thrombolysis (Tenecteplase thrombolysis) — Xuanwu Hospital, Beijing. Tenecteplase is a fibrin-specific thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots by breaking down fibrin.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tenecteplase thrombolysis TARGET	Tenecteplase thrombolysis	Xuanwu Hospital, Beijing	marketed	Fibrinolytic agent / Thrombolytic	Fibrin; Plasminogen
reteplase 10+10 U	reteplase 10+10 U	Sahlgrenska University Hospital	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA) analog	Fibrin; plasminogen
Oral lumbrokinase DLBS1033	Oral lumbrokinase DLBS1033	Universitas Sebelas Maret	marketed	Fibrinolytic enzyme	Fibrin; plasminogen activation pathway
Reteplase 10 U	Reteplase 10 U	The University of Texas Health Science Center, Houston	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Fibrin; plasminogen
TNKase	TNKase	Cedars-Sinai Medical Center	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Fibrin; plasminogen
Intra-Arterial TNK and Albumin	Intra-Arterial TNK and Albumin	Tianjin Huanhu Hospital	phase 3	Thrombolytic agent with albumin carrier	Fibrin; plasminogen
thrombolysis therapy	thrombolysis therapy	Leiden University Medical Center	phase 3	Thrombolytic agent	Fibrin; plasminogen/plasmin pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent / Thrombolytic class)

1. All India Institute of Medical Sciences · 1 drug in this class
2. Angde Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
3. Beijing Chao Yang Hospital · 1 drug in this class
4. Beijing Tiantan Hospital · 1 drug in this class
5. Life Recovery Systems · 1 drug in this class
6. Tasly Biopharmaceuticals Co., Ltd. · 1 drug in this class
7. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
8. Thrombolex, Inc. · 1 drug in this class
9. Tianjin Huanhu Hospital · 1 drug in this class
10. University of North Carolina, Chapel Hill · 1 drug in this class